Promising Biotech Stocks To Keep An Eye On – March 3rd

AbbVie, Thermo Fisher Scientific, TG Therapeutics, Danaher, Vertex Pharmaceuticals, IQVIA, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that develop and commercialize products based on biological processes, often focusing on medical therapies, diagnostics, and related healthcare innovations. These stocks can be highly volatile due to the significant risks associated with research and development, regulatory approvals, and market competition, but they also offer the potential for substantial rewards when groundbreaking treatments succeed. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded up $2.30 during trading hours on Monday, hitting $211.33. The stock had a trading volume of 2,508,491 shares, compared to its average volume of 5,965,071. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. The firm has a 50-day moving average price of $184.42 and a 200 day moving average price of $186.91. AbbVie has a fifty-two week low of $153.58 and a fifty-two week high of $212.09. The firm has a market capitalization of $373.07 billion, a price-to-earnings ratio of 88.07, a PEG ratio of 1.62 and a beta of 0.58.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO traded down $3.26 during trading hours on Monday, hitting $525.70. The stock had a trading volume of 764,656 shares, compared to its average volume of 2,001,633. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a 50-day moving average price of $549.37 and a 200 day moving average price of $564.91. The firm has a market capitalization of $198.33 billion, a price-to-earnings ratio of 31.80, a PEG ratio of 2.99 and a beta of 0.77. Thermo Fisher Scientific has a fifty-two week low of $493.30 and a fifty-two week high of $627.88.

TG Therapeutics (TGTX)

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

NASDAQ:TGTX traded up $5.66 during trading hours on Monday, reaching $35.75. 6,045,537 shares of the company were exchanged, compared to its average volume of 2,248,403. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock’s 50-day moving average is $30.75 and its 200-day moving average is $28.14. The firm has a market cap of $5.56 billion, a PE ratio of -354.26 and a beta of 2.26. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $36.84.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

NYSE:DHR traded down $0.24 during trading hours on Monday, reaching $207.52. 919,067 shares of the company were exchanged, compared to its average volume of 4,489,135. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock’s 50-day moving average is $224.58 and its 200-day moving average is $244.76. The firm has a market cap of $148.32 billion, a PE ratio of 39.31, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. Danaher has a twelve month low of $196.80 and a twelve month high of $281.70.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ:VRTX traded up $7.82 during trading hours on Monday, reaching $487.61. 382,495 shares of the company were exchanged, compared to its average volume of 1,489,109. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average is $440.39 and its 200-day moving average is $460.98. The firm has a market cap of $125.21 billion, a PE ratio of -221.45, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Shares of NYSE IQV traded down $0.54 during mid-day trading on Monday, reaching $188.26. The company’s stock had a trading volume of 512,725 shares, compared to its average volume of 1,421,435. The stock has a 50-day moving average of $199.13 and a two-hundred day moving average of $214.65. The stock has a market capitalization of $33.15 billion, a P/E ratio of 25.10, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA has a 1-year low of $184.66 and a 1-year high of $261.73.

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Shares of NYSE COR traded up $3.02 during mid-day trading on Monday, reaching $256.56. The company’s stock had a trading volume of 342,889 shares, compared to its average volume of 1,474,161. The stock has a 50-day moving average of $241.71 and a two-hundred day moving average of $237.85. The stock has a market capitalization of $49.75 billion, a P/E ratio of 36.48, a P/E/G ratio of 1.31 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora has a 1-year low of $214.77 and a 1-year high of $262.26.